Prucalopride and Linaclotide

Mechanism

Mechanism of action

Prucalopride: It is a selective, high-affinity serotonin type 4 receptor (5-HT₄) agonist, which does not interfere with other serotonin receptors or cardiac hERG channels. Its activation of myenteric 5-HT₄ receptors coordinately stimulates the release of acetylcholine in colonic neurons, enhancing high-amplitude colonic mass movements (massive peristalsis), facilitating distal fecal propulsion and accelerating global colonic transit.

Linaclotide: It is a synthetic peptide of 14 amino acids that acts locally as an agonist of the guanylate cyclase-C (GC-C) receptor, located on the luminal surface of the enterocytes of the intestinal epithelium.

Molecular Mechanism of Linaclotide

Selective binding of linaclotide to guanylate cyclase-C (GC-C) stimulates the intracellular conversion of GTP to cyclic guanosine monophosphate (cGMP). The increase in intracellular cGMP activates cGMP-dependent protein kinase II (PKG II), which phosphorylates and increases the conductance of the cystic fibrosis transmembrane conductance regulator (CFTR chloride channel). This causes the massive and coordinated secretion of chloride ions (Cl^-) and bicarbonate (HCO₃^-) into the intestinal lumen.

The resulting electrochemical gradient passively draws sodium ions (Na⁺) and water into the intestinal lumen, accelerating colonic transit and softening feces. Furthermore, cGMP is actively secreted into the extracellular space of the lamina propria, where it decreases the excitability of visceral afferent nociceptive fibers, selectively relieving the pain and visceral hypersensitivity characteristic of IBS-C.

Pharmacokinetics

Pharmacokinetics

• Absorption:
  • Prucalopride: High oral absorption. Bioavailability > 90%. It is not affected by food.
  • Linaclotide: Systemic bioavailability practically zero (< 0.1%). It exerts its local action exclusively in the lumen of the gastrointestinal tract. It is not measurable in plasma after usual doses.
• Metabolism and Excretion:
  • Prucalopride: It suffers little hepatic metabolism. More than 60% - 85% of the dose is excreted unchanged via the kidneys through active filtration. Half-life of 24 to 30 hours (allows dosing once a day).
  • Linaclotide: It is degraded in the intestinal lumen by natural proteolysis into its main active metabolite (MM-419447), which undergoes complete proteolytic degradation before fecal excretion.

Indicators and dose

Approved indications

• Prucalopride: Symptomatic treatment of chronic functional constipation in adults in whom conventional laxatives do not provide adequate relief.
• Linaclotide: Symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.

Dosage and Clinical Adjustment

Prucalopride (Adults):

• 2 mg orally once a day, at any time of day, with or without food.
• Elderly patients (>65 years): Start with a low dose of 1 mg once daily, with optional escalation to 2 mg if tolerated is adequate.

Linaclotide (Adults with IBS-C):

• 290 micrograms (µg) orally once a day, administered strictly 30 minutes before the first meal of the day (breakfast) to minimize the appearance of diarrhea.

Adjustment in Renal / Liver Failure:

• Prucalopride: In severe renal failure (eGFR < 30 mL/min), reduce the recommended daily dose to 1 mg. No adjustment required in Child-Pugh A/B liver failure; in severe insufficiency (Child-Pugh C), reduce the initial dose to 1 mg per day.
• Linaclotide: Does not require dose adjustments in patients with hepatic or renal insufficiency, as it is not appreciably absorbed systemically.

Security

Contraindications

• Prucalopride (Absolutas): Active mechanical gastrointestinal obstruction or perforation. Severe inflammatory bowel disease (complicated ulcerative colitis or Crohn's disease). Toxic megacolon. End-stage renal failure requiring dialysis (eGFR < 15 mL/min).
• Linaclotide (Absolutes): Suspected or confirmed mechanical gastrointestinal obstruction. Absolutely contraindicated in pediatric patients under 6 years of age (high risk of severe dehydration and death due to hyperstimulation of the CFTR channel).

Adverse effects (ADRs)

• Prucalopride: Transient headache (occurs in ≈ 25% of patients during the first day of therapy, self-limited by initial central serotonergic stimulation), nausea, diarrhea, diffuse abdominal pain.
• Linaclotide: Diarrhea (occurs in 20%, is dose-dependent and transient), flatulence, persistent abdominal pain, abdominal distension. Severe diarrhea requires temporary interruption or dose reduction to avoid dehydration and electrolyte imbalances.

Category in Pregnancy

Prucalopride: Limited data. Its use is not recommended during pregnancy. Women of childbearing potential should use effective contraception during active treatment.

Linaclotide: Considered acceptable with caution. Lacking systemic absorption and measurable transplacental passage, fetal exposure is negligible. However, the mother should be monitored to prevent electrolyte imbalances or dehydration due to pharmacological diarrhea.